



2022 ACR Annual Convergence Meeting Presenters

NOVEMBER 10, 2022

Facilitator: Roundtable 18 - Spondyloarthritis

Jose Scher, MD, Associate Professor
Roundtable 18 - Spondyloarthritis
4 to 5:25 pm

NOVEMBER 11, 2022

Examples from Rheumatology: Discovery of the VEXAS Syndrome

David B. Beck, MD, PhD, Assistant Professor
Basic and Clinical Research Conference
1:30 to 1:55 pm

Invited Speaker

Jose Scher, MD, Associate Professor
Review Course: Spondyloarthritis
9:45 to 11:15 am

NOVEMBER 12, 2022

Strain-Specific Glycan in a Gut Pathobiont Linked to Lupus Nephritis

Gregg Silverman, MD, Professor
Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes
3:20 to 3:35 pm

Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria

Jill Buyon, MD, Professor, Peter Izmirly, MD, Associate Professor, H. Michael Belmont, MD, Professor
SLE – Diagnosis, Manifestations, and Outcomes I: Renal Aspects
4 to 6 pm

Adenosine A2A Receptor Signaling Enhances Expression of an Endogenous p53 Mouse Variant in Bone Marrow Mesenchymal Stem Cells

Bruce N. Cronstein, MD, Professor
Osteoarthritis and Joint Biology – Basic Science Poster
1 to 3 pm

Dual (and Dueling) Fibroblast Differentiation Is Integral to the Pathogenesis of Anti-Ro Mediated Congenital Heart Block and Provides a Novel Biomarker of Severity

Robert Clancy, PhD, Professor, Amit Saxena, MD, Assistant Professor, Jill Buyon, MD, Professor
Pediatric Rheumatology – Basic Science Poster
1 to 3 pm

Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort

Jill Buyon, MD, Professor
SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis
1 to 3 pm

Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value

Amit Saxena, MD, Assistant Professor, Peter Izmirly, MD, Associate Professor, Jill Buyon, MD, Professor, H. Michael Belmont, MD, Professor
SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis
1 to 3 pm

Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Jill Buyon, MD, Professor
SLE – Treatment Poster I
1 to 3 pm

Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis

Amit Saxena, MD, Assistant Professor

SLE – Treatment Poster I

1 to 3 pm

A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)

Amit Saxena, MD, Assistant Professor

SLE – Treatment Poster I

1 to 3 pm

M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort

Jill Buyon, MD, Professor

Ignite Session 3C

1 to 3 pm

Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis

Jill Buyon, MD, Professor

Ignite Session 3C

1 to 3 pm

Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience

Jill Buyon, MD, Professor

Reproductive Issues in Rheumatic Disorders Poster

1 to 3 pm

Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study

Amit Saxena, MD, Assistant Professor

Ignite Session 7A

1 to 3 pm

Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial

Michael Pillinger, MD, Professor

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1 to 3 pm

NOVEMBER 13, 2022

Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features

Peter M. Izmirly, MD, Associate Professor, H. Michael Belmont, Professor, Robert Clancy, PhD, Professor, Jill P. Buyon, MD, Professor

Ignite Session 6A

9 to 10:30 am

Postoperative Flares and Peri-arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease

Jonathan Samuels, MD, Associate Professor

Ignite Session 2C

9 to 10:30 am

Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems

Rochelle L. Castillo, MD, Instructor, Rebecca Haberman, MD, Assistant Professor, Jose Scher, MD, Associate Professor

Ignite Session 6A

1 to 3 pm

Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus

Joshua Novack, MD, Resident, Stephen Honig, MD, Associate Professor, Peter Izmirly, MD, Associate Professor, H. Michael Belmont, MD, Professor, Jill Buyon, MD, Professor, Amit Saxena, MD, Assistant Professor

Ignite Session 2C

1 to 3 pm

Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiONal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

H. Michael Belmont, MD, Professor

Ignite Session 4C

9 to 10:30 am

Invited Speaker: Emerging Pathways: A Kinase Involved in Multiple Rheumatic Diseases

Jose Scher, MD, Associate Professor

Industry Supported Symposium

6:30 to 8:30 pm

Invited Speaker: Rheum for Improvement: axial SpA and PsA

Fardina Malik, MD, Assistant Professor

Industry Supported Symposium

6:30 to 8:30 pm

Moderator: Plenary Session II

Gregg Silverman, MD, Professor

Plenary II

11:30 am to 1:00 pm

Moderator: Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

Michael Pillinger, MD, Professor

RA – Treatment I: Switching or Discontinuation of Therapies

3 to 4:30 pm

Moderator: Abstracts: RA – Treatment II: Pre- and Early Disease

Rebecca Haberman, MD, Assistant Professor

Abstracts: RA – Treatment II: Pre- and Early Disease

4:30 to 6 pm

Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial

Michael Pillinger, MD, Professor

Metabolic and Crystal Arthropathies – Basic and Clinical Science

3 to 4:30 pm

Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment

Jill Buyon, MD, Professor

SLE – Etiology and Pathogenesis Poster

9 to 10:30 am

Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity

Robert Clancy, PhD, Professor, Peter Izmirly, MD, Associate Professor, Jill Buyon, MD, Professor

SLE – Etiology and Pathogenesis Poster

9 to 10:30 am

The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis

H. Michael Belmont, MD, Professor

SLE – Etiology and Pathogenesis Poster

9 to 10:30 am

Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

Jill Buyon, MD, Professor, Peter Izmirly, MD, Associate Professor, H. Michael Belmont, MD, Professor

SLE – Etiology and Pathogenesis Poster

9 to 10:30 am

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository

H. Michael Belmont, MD, Professor

Antiphospholipid Syndrome Poster

9 to 10:30 am

Single Antiphospholipid Antibody Positive Thrombotic APS Patients' Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)

H. Michael Belmont, MD, Professor
Antiphospholipid Syndrome Poster
9 to 10:30 am

Population Based Prevalence and Incidence of Mixed Connective Tissue Disease from the Manhattan Lupus Surveillance Program

Jill Buyon, MD, Professor, H. Michael Belmont, MD, Professor, Peter Izmirly, MD, Associate Professor
Epidemiology and Public Health Poster I
9 to 10:30 am

Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy

Jonathan Samuels, MD, Associate Professor
Orthopedics, Low Back Pain, and Rehabilitation Poster
9 to 10:30 am

Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers

Peter Izmirly, MD, Associate Professor, Amit Saxena, MD, Assistant Professor, H. Michael Belmont, MD, Professor, Julie Nusbaum, MD, Assistant Professor, Bruce Solitar, MD, Clinical Associate Professor, Fardina Malik, MD, Assistant Professor, Paula Rackoff, MD, Clinical Associate Professor, Rebecca Haberman, MD, Robert Clancy, PhD, Professor, Jill Buyon, MD, Professor
Reproductive Issues in Rheumatic Disorders Poster
9 to 10:30 am

Assessment and Application of Royal College of Obstetricians and Gynaecologists (RCOG) Risk Scores in the Prevention of Venous Thromboembolism Peri- and Postpartum in Systemic Lupus Erythematosus

Julie Nusbaum, MD, Assistant Professor, Peter Izmirly, MD, Associate Professor, H. Michael Belmont, MD, Professor, Jill Buyon, MD, Professor
Reproductive Issues in Rheumatic Disorders Poster
9 to 10:30 am

Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis

Amit Saxena, MD, Assistant Professor

SLE – Treatment Poster II

9 to 10:30 am

Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study

Jose Scher, MD, Associate Professor

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9 to 10:30 am

Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis

Rebecca Haberman, MD, Assistant Professor, Malavika Attur, MD, Associate Professor, Soumya M. Reddy, MD, Assistant Professor, Jose Scher, MD, Associate Professor

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9 to 10:30 am

Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis

Jose Scher, MD, Associate Professor

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9 to 10:30 am

Accuracy of Financial Disclosures in American-Based Rheumatology Journals

Michael Pillinger, MD, Professor

Measures and Measurement of Healthcare Quality Poster

1 to 3 pm

Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program

Brendan Denvir, MD, Resident, Jill Buyon, MD, Professor, H. Michael Belmont, MD, Professor, Kelly Corbitt, DO, Rheumatology Fellow, Peter Izmirly, MD, Associate Professor

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1 to 3 pm

Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria

Jill Buyon, MD, Professor

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1 to 3 pm

Urine ALCAM Is a Strong Predictor of Lupus Nephritis

Jill Buyon, MD, Professor

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1 to 3 pm

Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet's Disease

Johannes Nowatzky, MD, Assistant Professor

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1 to 3 pm

Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS

David B. Beck, MD, PhD, Assistant Professor

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1 to 3 pm

NOVEMBER 14, 2022

COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave

Fardina Malik, MD, Assistant Professor

Poster Session D

1 to 3 pm

Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study

Michael Pillinger, MD, Professor

Ignite Session 4B

1 to 3 pm

Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials

Michael Pillinger, MD, Professor

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1 to 3 pm

Immunology Bootcamp II: Principles in Practice

Gregg Silverman, MD, Professor

Scientific Session: Immunobiology

5 to 6 pm

Session Moderator

Michael Pillinger, MD, Professor

Gout is an autoinflammatory metabolic disease

10:30 to 11:30 am

Moderator: Late Breaking Abstracts

Gregg Silverman, MD, Professor

Late Breaking Abstracts

9 to 10:30 am

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth

Peter Izmirly, MD, Associate Professor, Jill Buyon, MD, Professor

Abstracts: Reproductive Issues in Rheumatic Disorders

10:30 to 11:30 am

Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile

Gregg Silverman, MD, Professor, Peter Izmirly, MD, Associate Professor, Jill Buyon, MD, Professor

SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

3 to 4:30 pm

Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

H. Michael Belmont, MD, Professor

Abstracts: Antiphospholipid Syndrome

5 to 6 pm

Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

H. Michael Belmont, MD, Professor

Antiphospholipid Syndrome

5 to 6 pm

Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans

Michael Toprover, MD, Assistant Professor, Michael Pillinger, MD, Professor

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1 to 3 pm

Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists

Michael Pillinger, MD, Professor

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1 to 3 pm

Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease

Gary Ho, MD, Clinical Assistant Professor, Michael Toprover, MD, Assistant Professor, Michael Pillinger, MD, Professor

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1 to 3 pm

Colchicine for Treatment of OsteoArthritis of the Knee (CLOAK)-A Double-blind, Placebo-controlled Trial

Jonathan Samuels, MD, Associate Professor, Michael Pillinger, MD, Professor, Michael Toprover, MD, Assistant Professor

Osteoarthritis – Clinical Poster

1 to 3 pm

Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis

Rebecca Blank, MD, PhD, Instructor, Jose Scher, MD, Associate Professor

RA – Treatment Poster IV

1 to 3 pm

Practical Strategies for the Management of Uncontrolled Gout

Michael Pillinger, MD, Professor

Activity Chair, Vindico-sponsored Continuing Education Session

AWARDS

Distinguished Fellow

Rebecca Blank, MD, PhD, Instructor

Master of the ACR

H. Michael Belmont, MD, Professor